Regional Autonomy Can Fracture the Global Strategy.

One Idea Worth Acting On.

A regional medical team funds an investigator-initiated trial to answer a local clinical question.

Months later the data is published.

The results directly contradict the company's global scientific narrative.

The launch team wakes up to a crisis they did not know existed.

The company is competing against its own data.

What's Actually Happening

Global and regional teams in oncology are often operating from different strategic playbooks. Global focuses on long-term scientific positioning and unified messaging. Regional focuses on local physician relationships, country-specific evidence needs, and market reimbursement requirements.

Both are legitimate. The collision becomes dangerous when local research runs without visibility into the global scientific narrative.

As Dr. Robert Matheis, President and CEO of ISMPP and contributor to Voices of Oncology, describes it: discovering that publicly presented data contradicts the company's global scientific strategy is a very bad day for leadership. The damage extends far beyond one publication — it weakens scientific credibility, launch consistency, payer confidence, and long-term brand trust.

Investigator-sponsored and investigator-initiated trials are where this fracture is most common. A country team funds a local study exploring endpoints, combinations, or patient populations that the global organization does not know about. No centralized mechanism maps local research back to the global scientific narrative. The company generates conflicting evidence around its own asset.

Why This Matters

Clinical narratives in oncology are fragile. When the market sees conflicting data from the same sponsor, trust erodes — among physicians, payers, guideline committees, and regulators simultaneously.

Once contradictory evidence is in the public domain, it cannot be unpublished. The global team must now spend time, resources, and credibility managing a narrative problem that a single alignment conversation might have prevented.

Uncoordinated evidence generation does not create strategic strength. It creates strategic noise that the company has to spend years cleaning up.

Where It Breaks in the Real World

A global Scientific Communications Platform — built over years to establish a unified voice across the healthcare ecosystem — is undermined by a single regional publication that used a different patient population definition, a different comparator, and reached a different conclusion.

The publication was never designed to cause harm. The regional team was doing exactly what it was incentivized to do: respond to local needs quickly. The problem was structural. There was no mechanism requiring the regional team to check the study design against the global scientific narrative before the investigation began.

What Needs to Change

Regional autonomy in evidence generation is not the problem. The absence of a global visibility mechanism is.

Every investigator-sponsored trial (IST) and investigator-initiated trial (IIT) involving a company asset should have a defined notification pathway to global Scientific Communications before the study design is finalized — not to block local research, but to ensure local research does not undermine the global evidence architecture the company depends on.

The organizations getting this right are not slowing down their regional teams. They are connecting them.

The Bottom Line

Regional agility is an asset. Regional fragmentation is a liability. The difference is a single alignment step that most organizations have never made mandatory.

Add Your Voice — Where are you seeing this? What's working — and what's not?